Source: Senator Ron Johnson’s YouTube channel

video

Senator Ron Johnson held a hearing November 19, 2020 to discuss the current state of the COVID-19 pandemic.

‘Early Outpatient Treatment’ from the Homeland Security and Governmental Affairs Committee hearing – Examining the US Approach to Early Covid-19 Treatments.

“There are moments in medicine, moments in our history when you have to allow doctors to practice medicine to develop these therapies, and that’s been the history, quite honestly of the development of medicine.

“My point is to talk about the bill I championed through Congress – Right to Try. Now, the current situation for example with hydroxychloroquine is not a prime example of Right to Try because hydroxychloroquine is a fully approved drug. What Right to Try says is that if a drug has gone through the first two stages, of FDA approval, so it’s been proven safe, but hasn’t gone through the final efficacy approval, a patient and a doctor still have the right to try that if there are no other available treatments.

“Isn’t that the position we’re in, in early treatment of Covid? There are no other treatments. And yet, doctors who’ve had the courage to practice medicine, and try things like ivermectin or hydroxychloroquine, have been scorned and worse.

“It makes no sense to me whatsoever.







Related: ‘Only a one in 17 billion chance hydroxychloroquine doesn’t work’: medical professor

A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.

Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19: A Meta-Analysis of 27 Studies and 44,684 Patients

HCQ Protocols from America’s Frontline Doctors

In 2003, the effects of chloroquine/HCQ on viral infections were known: an old drug pitted against SARS and HIV

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »